Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.1 , No. 2, Publication Date: Jul. 7, 2014, Page: 12-16
 pharmacology for the prevention of the stent thrombosis and myocardial infarctions following many different types of coronary syndromes.The conversion of clopidogrel; which is a prodrug, to its active metabolite is mediated by the cytochrome P450 (CYP).The CYP450 metabolic activation of clopidogrel has proposed about if the competition and/or the inhibitor medications for these isoenzymes may reduce or limit the clopidogrel therapeutic effectiveness.The identification of such an impact will be of the higher importance with the group of drugs called the Proton Pump Inhibitors (PPIs) as many of which are CYPC19 inhibitors.Unless for the Omeprazole. Limited numbers of non-confirmed data were existed concerning the influence of the interaction between the other PPIs (such as Rabeprazole and Pantoprazole) and the therapeutic effectiveness of clopidogrel.This study sought to examine the effects of PPI’s pantoprazole and rabeprazole co-administered with clopidogrel in patients with ischemic heart disease and peripheral vascular disease. Our clinical research data show that platelet aggregation was significantly higher in patients who were under rabeprazoletreatment at the time of the platelet function test; on the other hand, such attenuating effect on the platelet response to clopidogrel was not seen in patients on pantoprazole.Till further evidence becomes available, patients on clopidogrel maintenance therapy should be reevaluated for PPI use. Those having well-controlled symptoms may be candidates for either Rabeprazole or pantoprazole. Patients with history of gastrointestinal bleed will require gastroprotection in the form of PPIs. In such cases, pantoprazole should be the preferred PPI.&picture=http://www.aascit.org/aascit/decorators/img/journal/922.jpg)
| [1] | Mootaz M. Salman, Biomedical Research Center, Sheffield Hallam University, Sheffield, UK. |
| [2] | Al-mashhadany Mohammed S., FICMS Cardiothoracic and vascular surgery, Al-Salam Teaching Hospital, Mosul, Iraq. |
| [3] | Kalandar Ola O., Clinical Pharmacist, Al-Salam Teaching Hospital, Mosul, Iraq. |
| [4] | Yashaswini Srinivas, Research associate-Pharmacology at Indfrag Limited, India. |
Clopidogrel is a mainstay therapy in the cardiovascular (CVS) pharmacology for the prevention of the stent thrombosis and myocardial infarctions following many different types of coronary syndromes.The conversion of clopidogrel; which is a prodrug, to its active metabolite is mediated by the cytochrome P450 (CYP).The CYP450 metabolic activation of clopidogrel has proposed about if the competition and/or the inhibitor medications for these isoenzymes may reduce or limit the clopidogrel therapeutic effectiveness.The identification of such an impact will be of the higher importance with the group of drugs called the Proton Pump Inhibitors (PPIs) as many of which are CYPC19 inhibitors.Unless for the Omeprazole. Limited numbers of non-confirmed data were existed concerning the influence of the interaction between the other PPIs (such as Rabeprazole and Pantoprazole) and the therapeutic effectiveness of clopidogrel.This study sought to examine the effects of PPI’s pantoprazole and rabeprazole co-administered with clopidogrel in patients with ischemic heart disease and peripheral vascular disease. Our clinical research data show that platelet aggregation was significantly higher in patients who were under rabeprazoletreatment at the time of the platelet function test; on the other hand, such attenuating effect on the platelet response to clopidogrel was not seen in patients on pantoprazole.Till further evidence becomes available, patients on clopidogrel maintenance therapy should be reevaluated for PPI use. Those having well-controlled symptoms may be candidates for either Rabeprazole or pantoprazole. Patients with history of gastrointestinal bleed will require gastroprotection in the form of PPIs. In such cases, pantoprazole should be the preferred PPI.
Keywords
Clopidogrel, Plavix, Proton Pump Inhibitors, PPIs, P2Y12, Anticoagulant, Drug interactions
Reference
| [01] | Aubert RE, Epstein RS, Teagarden JR. Abstract 3998: Proton pump inhibitors effect on clopidogrel effectiveness: The Clopidogrel Medco Outcomes Study. Circulation 2008; 118: S815. |
| [02] | Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209. |
| [03] | Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-09. |
| [04] | Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363:1909-17. |
| [05] | Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2 nd , Lachno DR, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-31. |
| [06] | Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-58. |
| [07] | Dunn SP, Macaulay TE, Brennan DM. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008;118:815A. |
| [08] | Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;5:256-60. |
| [09] | Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44. |
| [10] | Juhász M, Herszényi L, Tulassay Z. Current Standings of the Proton Pump Inhibitor and Clopidogrel Co-Therapy: Review on an Evolving Field with the Eyes of the Gastroenterologist. Digestion 2010;81:10-5. |
| [11] | Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-8. |
| [12] | Label of Plavix (Clopidogrel bisulphate). [Updated on 2010 mar 12] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020839s042lbl.pdf . [accessed on 2014 mar 16]. |
| [13] | Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003;107:32-7. |
| [14] | Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7. |
| [15] | Majerus PW, Tollefsen DM. Drugs acting on blood and blood forming organs; blood coagulation and anti-coagulant, thrombolytic, and antiplatelet drugs: Introduction. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman′s The Pharmacological Basis of Therapeutics. 11 th ed. McGraw-Hill: New York; 2006. p. 1467-88. |
| [16] | O′Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet 2009;374:989-97. |
| [17] | Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009;120:2322-9. |
| [18] | Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992;44:527-32. |
| [19] | Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6. |
| [20] | Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-4. |
| [21] | Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-9. |
| [22] | Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75. |
| [23] | Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Available from: http://www.fda.gov/Drugs/......./ucm190787.htm . [Updated on 2009 Nov 17] [cited 2014 Mar. 29]. |
| [24] | Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. |
| [25] | Zairis MN, Tsiaousis GZ, Patsourakos NG, Georgilas AT, Kontos CF, Adamopoulou EN, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol 2010;26:e54-7 |
| [26] | Zuern CS, Geisler T, Lutilsky N, Winter S, Schwab M, Gawaz M. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res 2010;125:e51-4. |
| [27] | Hokimoto S., et al., (2014). Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation. Thromb Res. 2014 Apr;133(4):599-605. doi: 10.1016/j.thromres.2014.01.003. Epub 2014 Jan 9. |
| [28] | Kashour T., et al., (2014). Changing prescription pattern of omeprazole among patients receiving clopidogrel. Int Heart J. 2014;55(2):93-5. Epub 2014 Mar 14. |
| [29] | Funck-Brentano C., et al. (2013). Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Arch Cardiovasc Dis. 2013 Dec;106(12):661-71. doi: 10.1016/j.acvd.2013.09.002. Epub 2013 Nov 15. |
